UK's Cost Agency Not Ready To Back Gilead Sciences, Inc.'s Controversial Hepatitis C Drug
Published: Jun 17, 2014
(Reuters) - Britain's healthcare cost-effectiveness watchdog said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service.
The National Institute for Health and Care Excellence (NICE) said it was "minded not to recommend" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain.
Help employers find you! Check out all the jobs and post your resume.